Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Cabibbo G, Enea M, Attanasio M et al. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology 51(4), 1274–1283 (2010). •• A meta-analysis reporting survival of patients with hepatocellular carcinoma (HCC) who did not receive any treatment that provides a benchmark for the natural history of the disease.
  MedlineGoogle Scholar
• 2. Villa E, Critelli R, Lei B et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study. Gut 65(5), 861–869 (2016).
  Medline CASGoogle Scholar
• 3. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 69(1), 182–236 (2018).
  MedlineGoogle Scholar
• 4. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359(4), 378–390 (2008). •• The first randomized controlled trial that showed the benefit of sorafenib against placebo in advanced HCC.
  Medline CASGoogle Scholar
• 5. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet. Oncol. 10, 25–34 (2009).
  Medline CASGoogle Scholar
• 6. Forner A, Reig M, Bruix J et al. Hepatocellular carcinoma. Lancet. 391, 1301–1314 (2018).
  MedlineGoogle Scholar
• 7. Cucchetti A, Piscaglia F, Pinna AD et al. Efficacy and safety of systemic therapies for advanced hepatocellular carcinoma: a network meta-analysis of Phase III trials. Liver Cancer. 6, 337–348 (2017). • An indirect comparison among first-line systemic therapies for advanced HCC.
  Medline CASGoogle Scholar
• 8. Kudo M, Finn RS, Qin S et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised Phase III non-inferiority trial. Lancet 391, 1163–1173 (2018). • A noninferiority randomized controlled trial that led to the approval of lenvatinib as an alternative to sorafenib for first-line treatment of advanced HCC.
  Medline CASGoogle Scholar
• 9. Bruix J, Qin S, Merle P et al. RESORCE investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet 389, 56–66 (2017).
  Medline CASGoogle Scholar
• 10. Abou-Alfa GK, Meyer T, Cheng AL et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 379(1), 54–63 (2018).
  Medline CASGoogle Scholar
• 11. Zhu AX, Kang YK, Yen CJ et al. REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, Phase III trial. Lancet. Oncol. 20(2), 282–296 (2019).
  Medline CASGoogle Scholar
• 12. Iavarone M, Cabibbo G, Piscaglia F et al. SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54, 2055–2063 (2011).
  Medline CASGoogle Scholar
• 13. Reig M, Torres F, Rodriguez-Lope C et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J. Hepatol. 61, 318–324 (2014).
  Medline CASGoogle Scholar
• 14. Cammà C, Cabibbo G, Petta S et al. WEF study group; SOFIA study group. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology 57, 1046–1054 (2013).
  Medline CASGoogle Scholar
• 15. Reig M, Rimola J, Torres F et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58, 2023–2031 (2013).
  Medline CASGoogle Scholar
• 16. Iavarone M, Cabibbo G, Biolato M et al. Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib. Hepatology 62, 784–791 (2015). •• A field-practice study which evaluated post sorafenib survival, according to the reasons for its discontinuation.
  Medline CASGoogle Scholar
• 17. Riley RD, Lambert PC, Abo-Zaid G et al. Meta-analysis of individual participant data: rationale, conduct, and reporting. BMJ 340, c221 (2010).
  MedlineGoogle Scholar
• 18. Tudur Smith C, Dwan K, Altman DG et al. Sharing individual participant data from clinical trials: an opinion survey regarding the establishment of a central repository. PLoS ONE 9, e97886 (2014).
  MedlineGoogle Scholar
• 19. Guyot P, Ades AE, Ouwens MJ et al. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med. Res. Methodol. 1, 12–19 (2012).
  Google Scholar
• 20. Shamseer L, Moher D, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 350, g7647 (2015).
  MedlineGoogle Scholar
• 21. Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials 17, 1–12 (1996).
  Medline CASGoogle Scholar
• 22. Bañares R, Albillos A, Rincón D et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: a meta-analysis. Hepatology 35, 609–615 (2002).
  MedlineGoogle Scholar
• 23. Llovet JM, Di Bisceglie AM, Bruix J et al. Panel of experts in HCC-design clinical trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J. Natl Cancer Inst. 100, 698–711 (2008).
  MedlineGoogle Scholar
• 24. Combescure C, Foucher Y, Jackson D et al. Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects. Stat. Med. 33, 2521–2537 (2014).
  MedlineGoogle Scholar
• 25. Johnson PJ, Qin S, Park JW et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized Phase III BRISK-FL study. J. Clin. Oncol. 31, 3517–3524 (2013).
  Medline CASGoogle Scholar
• 26. Cheng AL, Kang YK, Lin DY et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized Phase III trial. J. Clin. Oncol. 31, 4067–4075 (2013).
  Medline CASGoogle Scholar
• 27. Cainap C, Qin S, Huang WT et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized Phase III trial. J. Clin. Oncol. 33, 172–179 (2015).
  Medline CASGoogle Scholar
• 28. Zhu AX, Rosmorduc O, Evans TR et al. SEARCH: a Phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 33, 559–566 (2015).
  Medline CASGoogle Scholar
• 29. Vilgrain V, Pereira H, Assenat E et al. SARAH Trial Group. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled Phase III trial. Lancet. Oncol. 18, 1624–1636 (2017).
  Medline CASGoogle Scholar
• 30. Chow PKH, Gandhi M, Tan SB et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J. Clin. Oncol. 36(19), 1913–1921 (2018).
  Medline CASGoogle Scholar
• 31. Kudo M, Ueshima K, Yokosuka O et al. Sorafenib plus low-dose cisplatin and fluorouracil hepatic arterial infusion chemotherapy versus sorafenib alone in patients with advanced hepatocellular carcinoma (SILIUS): a randomised, open label, Phase III trial. Lancet Gastroenterol. Hepatol. 3, 424–432 (2018).
  MedlineGoogle Scholar
• 32. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol.. 19(14), 135 (2014).
  Google Scholar
• 33. Giannini EG, Bucci L, Garuti F et al. Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice. Hepatology 67, 1784–1796 (2018).
  Medline CASGoogle Scholar
• 34. Bruix J, Cheng AL, Meinhardt G et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two Phase III studies. J. Hepatol. 67, 999–1008 (2017). • A pooled analysis that focused on prognostic factors for HCC and predictive factors of sorafenib benefit.
  Medline CASGoogle Scholar
• 35. Jackson R, Psarelli EE, Berhane S et al. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized Phase III trials. J. Clin. Oncol 35, 622–628 (2017).
  MedlineGoogle Scholar
• 36. Cabibbo G, Petta S, Barbara M et al. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J. Hepatol. 67, 65–71 (2017). • A prospective study which showed that hepatic decompensation is the main driver of mortality in patients with successfully treated early HCC who did not receive antiviral therapy for HCV.
  MedlineGoogle Scholar
• 37. Cabibbo G, Celsa C, Calvaruso V et al. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. J. Hepatol. 71 (2), 265–273 (2019). •• The first evidence that direct-acting antivirals prolong overall survival in patients with successfully treated early HCC.
  Medline CASGoogle Scholar
• 38. Cabibbo G, Celsa C, Cammà C et al. Should we cure hepatitis C virus in patients with hepatocellular carcinoma while treating cancer? Liver Int. 38(12), 2108–2116 (2018).
  MedlineGoogle Scholar
• 39. Cabibbo G, Petta S, Barbàra M et al. A meta-analysis of single HCV-untreated arm of studies evaluating outcomes after curative treatments of HCV-related hepatocellular carcinoma. Liver Int. 37(8), 1157–1166 (2017).
  Medline CASGoogle Scholar
• 40. Marrero JA, Kudo M, Venook AP et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J. Hepatol. 65(6), 1140–1147 (2016).
  Medline CASGoogle Scholar
• 41. Vale CL, Tierney JF, Stewart LA Effects of adjusting for censoring on meta-analyses of time-to-event outcomes. Int. J. Epidemiol. 31(1), 107–111 (2002).
  MedlineGoogle Scholar